Skip to main content
SpringerLink
Log in
Book cover

Drug-Induced Hepatotoxicity pp 367–394Cite as

Effect of Liver Disease on Drug Metabolism and Pharmacokinetics

  • Chapter

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 121))

Abstract

The processes of drug absorption, distribution, metabolism and excretion, and the rates at which they occur, are recognized as critical factors influencing the degree and time course of drug pharmacologic action in the body. Disease states affecting different organs may have a variety of effects on drug disposition and also on pharmacologic and pharmacodynamic effects. The two organs that are recognized as having the greatest influence on drug disposition, either directly or indirectly, are the kidney and the liver. While most clinical studies carried out early in drug development are conducted in healthy subjects. renal or hepatic impairment may exert a considerable influence on both the disposition and the pharmacodynamic consequences of an administered drug.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abernethy DR (1989) The pharmacokinetic profile of amlodipine. Am Heart J 118 (pt2)1100–1103

    PubMed  CAS  Google Scholar 

  • Abshagen U, Rennekamp H, Luszpinski G (1977) Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment. Eur J Clin Pharmacol 11:169–176

    PubMed  CAS  Google Scholar 

  • Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, Nicoli FB (1972) Kinetics of rafampicin and isoniazid administered alone and in combination to normal subjects and in patients with liver disease. Gut 13:47–53

    PubMed  CAS  Google Scholar 

  • Alvin J, McHorse T, Hoyumpa A, Bush MT, Schenker S (1975) The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther 192:224–235

    PubMed  CAS  Google Scholar 

  • Andreasen PB, Ranek L, Statland RE, Tygstrup N (1974) Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest 4:129

    PubMed  CAS  Google Scholar 

  • Arns PA, Wedlund PJ, Branch RA (1988) Adjustment of medications in liver failure. In: Chernow B (ed) The pharmacologic approach to the critically ill patient. Williams and Wilkins, Baltimore, pp 85–111

    Google Scholar 

  • Avant GR, Schenker S, Alford RH (1975) The effect of cirrhosis on the disposition and elimination of clindamycin. Am J Dig Dis 20:223–229

    PubMed  CAS  Google Scholar 

  • Azzollini F, Gazzaniga A, Lodola E, Natangelo R (1972) Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. Int J Clin Pharmacol 6:130–134

    PubMed  CAS  Google Scholar 

  • Barre J, Houin G, Brunner F, Bree F, Tillement J-P (1983) Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res 3:215–226

    PubMed  CAS  Google Scholar 

  • Barre J, Mallat A, Rosenbaum J, Deforges L, Houin G, Dhumeaux D, Tillement J-P (1987) Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 23:753–757

    PubMed  CAS  Google Scholar 

  • Bergrem H, Ritland S, Opedal I, Bergan A (1983) Prednisolone pharmacokinetics and protein binding in patients with portosystemic shunt. Scand J Gastroenterol 18:273–276

    PubMed  CAS  Google Scholar 

  • Blaschke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2:32–44

    PubMed  CAS  Google Scholar 

  • Branch RA (1982) Drugs as indicators of hepatic function. Hepatology 2:97–105

    PubMed  CAS  Google Scholar 

  • Branch RA, Shand DG (1976) Propranolol disposition in chronic liver disease: a physiological approach. Clin Pharmacokinet 1 :264–279

    PubMed  CAS  Google Scholar 

  • Branch RA. Herbert CM, Read AF(1973)Determinants of serum antipyrine half-lives in patients with liver disease. Gut 14:569–573

    PubMed  CAS  Google Scholar 

  • Branch RA, James J, Read AE (1976a) A study of factors influencing drug disposition in chronic liver disease using the model drug (+)-propranolol. Br J Clin Pharmacol 3:243–249

    PubMed  CAS  Google Scholar 

  • Branch RA, Morgan MH, James J, Read AE (1976b) Intravenous administration of diazepam in patients with chronic liver disease. Gut 17:975–983

    PubMed  CAS  Google Scholar 

  • Breimer DD (1983) Variability in human drug metabolism and its implications. Int J Clin Pharmacol Res 3:399–413

    PubMed  CAS  Google Scholar 

  • Breimer DD, Zilly W, Richter E (1975) Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. Clin Pharmacol Ther 18:433–440

    PubMed  CAS  Google Scholar 

  • Breimer DD, Lodewijks MThM, vanBrummelen P, vanHarten J, Wilson JHP (1986) Pharmacokinetics and haemodynamic effects of nisoldipine in patients with liver cirrhosis. Br J Pharmacol 89:482P

    Google Scholar 

  • Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220–239

    PubMed  CAS  Google Scholar 

  • Brown N, Ho DHW, Fong KL, Bogerd L. Maksymiuk A, Bolivar R, Fainstein V, Bodey GP(1983) Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 23:603–609

    PubMed  CAS  Google Scholar 

  • Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC (1983) Mezlocillin kinetics in hepatic insufficiency. Clin Pharmacol Ther 33:73–76

    PubMed  CAS  Google Scholar 

  • Burnett DA, Barak AJ. Tuma DJ. Sorrell MF(1976)Altered elimination of antipyrine in patients with acute viral hepatitis. Gut 17:341–344

    PubMed  CAS  Google Scholar 

  • Butterworth RF, Lovoie J, Giguere JF, Pomier-Layrargues G (1988) Affinities and densities of high affinity [3H]muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 8:1084–1088

    PubMed  CAS  Google Scholar 

  • Cello JP, Øie S (1983) Cimetidine disposition in patients with Laennec’s cirrhosis during multiple dosing therapy. Eur J Clin Pharmacol 25:223–229

    PubMed  CAS  Google Scholar 

  • Chopra S, Griffin PH (1985) Laboratory tests and diagnostic procedures in evaluation of liver disease. Am J Med 79:221–230

    PubMed  CAS  Google Scholar 

  • Cotting J, Reichen J, Kutz K, Laplanche R, Nuesch E (1990) Pharmacokinetics of isradipine in patients with chronic liver disease. Eur J Clin Pharmacol 38:599–603

    PubMed  CAS  Google Scholar 

  • Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD (1987) Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 4:330–336

    PubMed  CAS  Google Scholar 

  • DeGroen PC, McCallum OK, Moyer TP, Wiesner RH (1988) Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis.Transplant Proc 20 [Suppl 2]:509–511

    CAS  Google Scholar 

  • DuSouich P, Erill S (1977) Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease. Clin Pharmacol Ther 22:588–595

    CAS  Google Scholar 

  • Eagle CJ. Strunin L(1990)Drug metabolism in liver disease. Curr Anaesth Crit Care 1:204–212

    Google Scholar 

  • Echizen H, Eichelbaum M (1986) Clinical pharmacokinetics of verapamil, nifedipine, and diltiazem. Clin Pharmacokinet 11:425–429

    PubMed  CAS  Google Scholar 

  • Eichelbaum M, Mikus G, Mast V, Fischer C, Kuhlmann U, Machleidt C (1988) Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease.J Cardiovasc Pharmacal 12 [Suppl 4]:S6–S10

    CAS  Google Scholar 

  • Finucci GF, Padrini R, Piovan D, Melica E, Merkel C, Gatta A, Zuin R (1988) Verapamil pharmacokinetics and liver function in patients with cirrhosis. Int J Clin Pharmacol Res 8:123–126

    PubMed  CAS  Google Scholar 

  • Fowler JM, Schafer DM (1981) A mechanism for the increased sensitivity to benzodiazepines in hepatocellular failure: evidence from an animal model. Gastroenterology 80:1359

    Google Scholar 

  • Goldberg DM, Brown D (1987) Advances in the application of biochemical tests to diseases of the liver and biliary tract: their role in diagnosis, prognosis, and elucidation of pathogenic mechanisms. Clin Biochem 20:127–148

    PubMed  CAS  Google Scholar 

  • Gonzalez G, Aransibia A, Rivas MI, Caro P, Antezana C (1982) Pharmacokinetics of frusemide in patients with hepatic cirrhosis. Eur J Clin Pharmacol 22:315–320

    PubMed  CAS  Google Scholar 

  • Hall KW, Nightingale CH, Gibaldi M, Nelson E, Bates TR, DiSanto AR (1982) Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. J Clin Pharmacol 22:321–325

    PubMed  CAS  Google Scholar 

  • Hathcock JN (1985) Nutrient and non-nutrient effects on drug metabolism. Drug Nutr Interactions 4:217–234

    CAS  Google Scholar 

  • Hattner RS, Engelstad BL (1983) Diagnostic imaging and quantitating physiologic function using radionuclide techniques in gastrointestinal disease. In: Sleisinger MH, Fordtran JS (eds) Gastrointestinal disease: pathophysiology, diagnosis, management, 3rd edn, vol 2. Saunders, Philadelphia, pp 1667–1688

    Google Scholar 

  • Hayes PC, Plevris JN, Bouchier IA (1989) Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J Hum Hypertens 3 [Suppl 1]:153–158

    PubMed  Google Scholar 

  • Held H, Fried F (1977) Elimination of para-aminosalicylic acid in patients with liver disease and renal insufficency. Chemotherapy 23:405–415

    PubMed  CAS  Google Scholar 

  • Hepner GW, Vesell ES (1975) Quantitative assessment of hepatic function by breath analysis after oral administration of [14C)aminopyrine. Ann Intern Med 83:632–638

    PubMed  CAS  Google Scholar 

  • Hinthorn DR, Baker LH, Romig DA, Hassanein K, Liu C (1976) Use of clindamycin in patients with liver disease. Antimicrob Agents Chemother 9:495–501

    Google Scholar 

  • Höffken G, Lode H, Koeppe P, Ruhnke M, Bomer K (1984) Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver. Chemotherapy 30:7–17

    PubMed  Google Scholar 

  • Hoffman TA, Cestero R, Bullock WE (1970) Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann Intern Med 73:173–178

    PubMed  CAS  Google Scholar 

  • Homeida A, Jackson L, Roberts CJC (1978) Decreased first-pass metabolism of labetolol in chronic liver disease. Br Med J 2:1048–1050

    PubMed  CAS  Google Scholar 

  • Horn T, Christoffersen P, Henriksen JH (1987) Alcoholic liver injury: defenestration in noncirrhotic liver - a scanning electron microscope study. Hepatology 7:77–82

    PubMed  CAS  Google Scholar 

  • Hoyumpa AM, Schenker S (1982) Major drug interactions: effect of liver disease, alcohol and malnutrition. Annu Rev Med 33:113–149

    PubMed  CAS  Google Scholar 

  • Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20:27–33

    PubMed  CAS  Google Scholar 

  • Kirch W, Schäfer-Korting M, Mutschler E, Ohnhaus EE, Braun W(1983)Clinical experience with atenolol in patients with chronic liver disease. J Clin Pharmcol 23:171–177

    CAS  Google Scholar 

  • Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE (1987) Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 13:110–117

    PubMed  CAS  Google Scholar 

  • Kleinbloesem CH, vanHarten J, Wilson JHP, Danhof M, vanBrummele P, Breimer DD (1986) Nifedipine: kinetics and hemodynamic effects in patients with cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 40:21–28

    PubMed  CAS  Google Scholar 

  • Klinger EL, Vaamonde CA, Vaamonde LS, Lancestremere RG, Morosi HJ, Frisch E, Papper S (1970) Renal function changes in cirrhosis of the liver. Arch Intern Med 125:1010–1015

    Google Scholar 

  • Klotz U, Antonin KH, Brugel H, Bieck PR (1977) Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther 21:430–436

    PubMed  CAS  Google Scholar 

  • Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347–359

    PubMed  CAS  Google Scholar 

  • Klotz U, Fischer C, Müller-Seydlitz P, Schulz J, Müller WA (1979) Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther 26:221–227

    PubMed  CAS  Google Scholar 

  • Klotz U, McHorse TS, Wilkinson GR (1974) The effect of cirrhosis on the disposition and elimination of meperidine (pethidine) in man. Clin Pharmacol Ther 16:667–675

    PubMed  CAS  Google Scholar 

  • Klotz U, Rapp T, Müller WA(1978)Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 13:55–60

    PubMed  CAS  Google Scholar 

  • Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR (1978) Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 24:4l1–419

    Google Scholar 

  • Kutt H, Winters W, Scherman R, McDowell F (1964) Diphenylhydantoin and phenobarbital toxicity. Arch Neurol 11:649–656

    PubMed  CAS  Google Scholar 

  • Lee BL, Wong D, Benowitz NL, Sullam PM (1993) Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 53:529–535

    PubMed  CAS  Google Scholar 

  • Lewis JH, Zimmerman HJ (1989) Drug-induced liver disease. Med Clin N Am 73:775–792

    PubMed  CAS  Google Scholar 

  • Maddison JE, Dodd PR, Morrison M, Johnston GA, Farrell GC (1987) Plasma GABA, GABA-like activity and the brain GABA-benzodiazepine receptor complex in rats with chronic hepatic encephalopathy. Hepatology 7:621–628

    PubMed  CAS  Google Scholar 

  • Mangioni A, Imhoff TE, Lee RV, Shum LY, Jusko WJ (1978) Pharmacokinetics of theophylline in hepatic disease. Chest 73:616– 622

    Google Scholar 

  • Marcantonio LA, Auld WHR, Murdoch WR, Purohit R, Skellern GG, Howes CA (1983) The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. Br J Clin Pharmacol 25:245–252

    Google Scholar 

  • Mawer GE, Miller NE, Turnberg LA (1972) Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol 4:549–560

    Google Scholar 

  • May GR (1986) Hepatobiliary imaging. In: Gitnick G (ed) Current hepatology. Year Book Medical Publishers, Chicago, pp 361–379

    Google Scholar 

  • Mazoit JX, Sandouk P, Scherrmann J-M, Roche A (1990) Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacal Ther 48:613–618

    CAS  Google Scholar 

  • McConnell JB, Curry SH, Davies M, Williams R (1982) Clinical effects and metabolism of diazepam in patients with chronic liver disease. Clin Sci 63:75–80

    PubMed  CAS  Google Scholar 

  • McHorse TS, Wilkinson GR, Johnson RF, Schenker S (1975) Effect of acute viral hepatitis in man on the disposition and elimination of meperidine. Gastroenterology 68:775–780

    PubMed  CAS  Google Scholar 

  • McLean AJ, Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21 :42–69

    PubMed  CAS  Google Scholar 

  • McQuinn RL, Pentikäinen PJ, Chang SF, Conrad GJ(1988)Pharmacokinetics of flecainide in patients with cirrhosis of the liver. Clin Pharmacol Ther 44:566–572

    PubMed  CAS  Google Scholar 

  • Miglioli PA, Pivetta P, Orlando R, Palatini P, Varotto A, Okolicsanyi L (1989) Pharmacokinetics in patients with liver cirrhosis. Chemotherapy 35:330–332

    PubMed  CAS  Google Scholar 

  • Mooney H, Roberts R, Cooksley WGE, Halliday JW, Powell LW (1985) Alterations in the liver with ageing. Clin Gastroenterol 14:757–771

    PubMed  CAS  Google Scholar 

  • Murray M (1992) P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 23: 132–146

    PubMed  CAS  Google Scholar 

  • Murray M, Zaluzny L, Farrell GC (1986) Drug metabolism in cirrhosis.Selective changes in cytochrome P450 isozymes in the choline-deficient rat model. Biochem Pharmacol 35:1817–1824

    PubMed  CAS  Google Scholar 

  • Neal EA, Meffin PJ, Gregory PB, Blascke TF (1979) Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 77:96–102

    PubMed  CAS  Google Scholar 

  • Ohnhaus EE, Münch U, Meier J(1982)Elimination of pindolol in liver disease. Eur J Clin Pharmacol 22:247–251

    PubMed  CAS  Google Scholar 

  • Ohnishi A, Tsuboi Y, Ishizaki T, Kubota K, Ohno T, Yoshida H, Kanezaki A, Tanaka T (1989) Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther 45:657–665

    PubMed  CAS  Google Scholar 

  • O’Mahony MS, Woodhouse KW (1994) Age, environmental factors and drug metabolism. Pharmacol Ther 61:279–287

    PubMed  Google Scholar 

  • Patwardhan R, Johnson R, Sheehan J, Desmond P, Wilkinson G, Hoyumpa A, Branch R, Schenker S (1981) Morphine metabolism in cirrhosis. Gastroenterology 8:1344

    Google Scholar 

  • Pentikäinen PJ, Hietakorpi S, Hainen MO, Lampinen LM (1986) Cirrhosis of the liver markedly impairs the elimination of mexiletine. Eur J Clin Pharmacol 30:83–88

    PubMed  Google Scholar 

  • Pentikäinen PJ, Neuvonen PJ, Tarpila S, Syvälahti E(1978)Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole. Br J Med 2:861–863

    Google Scholar 

  • Periti P, Mazzei T (1987) Pharmacokinetics of roxithromycin in renal and hepatic failure and drug interactions. J Antimicrob Chemother 20 [Suppl B]:107–112

    PubMed  Google Scholar 

  • Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou JP (1978) Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 74:566–571

    PubMed  CAS  Google Scholar 

  • Piafsky KM (1980) Disease-induced changes in the plasma binding of basic drugs. Clin pharmacokinet 5:246–262

    PubMed  CAS  Google Scholar 

  • Piafsky KM, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by diseaseinduced elevations of plasma α 1-acid glycoprotein. N Engl J Med 299:1435–1439

    PubMed  CAS  Google Scholar 

  • Pisani F, Perucca E, Primerano G, D’Agostino AA, Petrelli RM, Fazio A, Oteri G, DiPerri R (1984) Single-dose kinetics of primidone in acute viral hepatitis. Eur J Clin PharmacoI27:4165–4169

    Google Scholar 

  • Pond SM, Tong T, Benowitz NL, Jacob P (1979) Bioavailability and clearance of meperidine in patients with chronic liver disease. Clin Pharmacol Ther 25:242

    Google Scholar 

  • Pond SM, Tong T, Benowitz NL, Jacob P (1980) Enchanced bioiavailability of pethidine and pentozocine in patients with cirrhosis of the liver. Aust NZJ Med 10:515–519

    CAS  Google Scholar 

  • Powell JR, Okada R, Conrad KA, Guentert TW, Riegelman S (1982) Altered quinidine disposition in a patient with chronic active hepatitis. Postgrad Med J 58:82–84

    PubMed  CAS  Google Scholar 

  • Pugh RNH, Murray-Lyon JM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649

    PubMed  CAS  Google Scholar 

  • Quart BD, Gallo DG, Sami MH, Wood AJJ (1986) Drug interaction studies and encainide use in renal and hepatic impairment. Am J Cardiol 58:104c–113c

    PubMed  CAS  Google Scholar 

  • Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Lewis WJ (1990) The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. Clin Pharmacol Ther 47:463–469

    PubMed  CAS  Google Scholar 

  • Regårdh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C (1989) Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 36:473–479

    PubMed  Google Scholar 

  • Regårdh CG, Jordö L, Ervik M, Lundborg R, Olsson R, Rönn 0 (1981) Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet 6:375–388

    PubMed  Google Scholar 

  • Renner E, Horber FF, Jost G, Frey BM, Frey FJ (1986) Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 90:819–828

    PubMed  CAS  Google Scholar 

  • Roberts RK, Wilkinson GR, Branch RA, Schenker S (1978) Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology 75:479–485

    PubMed  CAS  Google Scholar 

  • Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications. Lea and Febiger, Philadelphia, pp 189–190

    Google Scholar 

  • Saudek F, Moravek J, Modr Z (1989) Cefoperozone pharmacokinetics in patients with liver cirrhosis, a predictive value of the ujoviridin test. Int J Clin Pharmacol Ther Toxicol 27:82–87

    PubMed  CAS  Google Scholar 

  • Schafer DF, Fowler IM, Munson PJ, Thakur AK, Waggoner JG, Jones EA (1983) Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med 102:870–880

    PubMed  CAS  Google Scholar 

  • Schalm SW, Summerskill WHJ, Go VLW (1977) Prednisone for chronic active liver disease: pharmacokinetics including conversion to prednisolone. Gastroenterology 72:910–913

    PubMed  CAS  Google Scholar 

  • Schentag JJ, Cerra FB, Calleri GM, Rose JQ, Leising ME, French MA, Bernhard H (1981) Age, disease and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 29:737–743

    PubMed  CAS  Google Scholar 

  • Secor JW, Schenker S (1987) Drug metabolism in patients with liver disease. Adv Intern Med 32:379–406

    PubMed  CAS  Google Scholar 

  • Shear L, Kleinerman J, Gabuzda GJ (1965) Renal failure in patients with cirrhosis of the liver. Am J Med 39:184–198

    PubMed  CAS  Google Scholar 

  • Shull HJ, Wilkinson GR, Johnson R, Schenker S (1976) Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 84:420–425

    PubMed  CAS  Google Scholar 

  • Siersema PD, Wilson JHP (1992) The effect of liver disease on drug metabolism. Eur J Intern Med 3:197–212

    Google Scholar 

  • Singh D, Vijayvargiya, Kakrani AL (1977) Activity and inducibility of hepatic microsomal enzymes in liver diseases. Indian J Med Res 66:832–839

    PubMed  CAS  Google Scholar 

  • Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, Schentag JJ (1984) Ranitidine disposition and systemic availability in hepatic cirrhosis. Clin Pharmacol Ther 35:487–494

    PubMed  CAS  Google Scholar 

  • Sotaniemi EA, Niemelä O, Risteli L, Stenbäck F, Pelkonen RO, Lahtela JT, Risteli J(1986)Fibrotic process and drug metabolism in alcoholic liver disease. Clin Pharmacol Ther 40:46–55

    PubMed  CAS  Google Scholar 

  • Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H (1987) Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 33:493–498

    PubMed  CAS  Google Scholar 

  • Stoeckel K, Tuerk H, Trueb V, McNamara PJ (1984) Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther 36:500–509

    PubMed  CAS  Google Scholar 

  • Storstein L, Amlie J (1975) Digitoxin pharmacokinetics in chronic active hepatitis. Digestion 12:353

    Google Scholar 

  • Suhrland LG, Weisberger AS (1963) Chloramphenicol toxicity in liver and renal disease. Arch Intern Med 112:161–168

    Google Scholar 

  • Tam YK (1993) Individual variation in first-pass metabolism. Clin Pharmacokinet 25:300–328

    PubMed  CAS  Google Scholar 

  • Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M (1973) Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 78:99–508

    Google Scholar 

  • Ueda H, Sakurai T, Ota M, Nakajima A, Kamii K, Maezawa H (1963) Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease. Diabetes 12:414–419

    PubMed  CAS  Google Scholar 

  • Vesell ES (1984) Noninvasive assessment in vivo of hepatic drug metabolism in health and disease. Ann NY Acad Sci 428:293–307

    PubMed  CAS  Google Scholar 

  • Villeneuve JP, Rocheleau F, Raymond G (1984) Triamterine kinetics and dynamics in cirrhosis. Clin Pharmacol Ther 35:831–837

    PubMed  CAS  Google Scholar 

  • Vincent P, Colombel JF, Husson MO, Izard D, Paris JC, Leclerc H (1988) Pharmacokinetics of cefotoxime in cirrhotic pateints with or without ascites. Presse Med 17 :2331–2334

    PubMed  CAS  Google Scholar 

  • Wallace S, Brodie MI (1976) Decreased drug binding in serum from patients with chronic hepatic disease. Eur J Clin Pharmacol 9:429–432

    CAS  Google Scholar 

  • Watson RGP, Bastain W, Larkin KA, Hayes JR, McAinsh JA, Shanks RG (1987) A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol 24:527–535

    PubMed  CAS  Google Scholar 

  • Welling PG (1986) Pharmacokinetics: processes and mathematics ACS monograph 185, American Chemical Society, Washington DC, pp a: 141, b: 142, c: 164, d: 166, e: 196,f: 258, g: 264

    Google Scholar 

  • Welling PG (1993) Pharmacokinetic principles: linear and nonlinear. In: Welling PG, de laIglesia FA (eds) Drug toxicokinetics. Marcel Dekker, New York, pp 19–41

    Google Scholar 

  • Wilkinson GR (1980) Influence of liver disease on pharmacokinetics. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics, principles of therapeutic drug monitoring. Applied Therapeutics, San Francisco, pp 57–75

    Google Scholar 

  • Williams RL, Blaschke TF, Meffin PJ, Melmon KI, Rowland MR (1976) Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and idocyamine green. Clin Pharmacol Ther 200:290–299

    Google Scholar 

  • Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M (1977) Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21:301–309

    PubMed  CAS  Google Scholar 

  • Williams RL, Mamelok RD (1980) Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 5:528–547

    PubMed  CAS  Google Scholar 

  • Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA (1978) The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokin 3:478–487

    CAS  Google Scholar 

  • Woodhouse KW (1985) Drugs and the ageing gut, liver and pancreas. Clin Gastroenterol 14:863–881

    PubMed  CAS  Google Scholar 

  • Yee GC, Kennedy MS, Storb R, Thomas ED (1984) Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. Blood 64:1277–1279

    PubMed  CAS  Google Scholar 

  • Zeneroli ML (1985) Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. J Hepatol 1:301–312

    PubMed  CAS  Google Scholar 

  • Zilly W, Breimer DD, Richter E (1978) Hexobarbital disposition in compensated and decompensated cirrhosis of the liver. Clin Pharmacol Ther 23:525–534

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. G. Welling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. F. Pool
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology Division of Experimental Pathology, University of Toronto, Medical Sciences Building, 1 King’s College Circle, M5S 1A8, Toronto, Ontario, Canada

    Ross G. Cameron M.D., Ph.D.

  2. Department of Clinical Biochemistry Banting Institute, University of Toronto, Room 521, 100 College Street, M5G 1L5, Toronto, Ontario, Canada

    George Feuer Ph.D.

  3. Parke-Davis Pharmaceutical Research Division Department of Pathology and Experimental Toxicology, Warner Lambert Company, 2800 Plymouth Road, 48105, Ann Arbor, MI, USA

    Felix A. de la Iglesia M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Welling, P.G., Pool, W.F. (1996). Effect of Liver Disease on Drug Metabolism and Pharmacokinetics. In: Cameron, R.G., Feuer, G., de la Iglesia, F.A. (eds) Drug-Induced Hepatotoxicity. Handbook of Experimental Pharmacology, vol 121. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61013-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61013-4_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64657-7

  • Online ISBN: 978-3-642-61013-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation